Tesamorelin 5mg

- Free Priority Shipping
- Orders over $75
Buy Tesamorelin 5mg :
| Unit Size | 5mg/vial |
| Unit Quantity | 1 vial |
| Purity (Mass Spectrometry and UV) | 99.91% |
| Sequence | (trans-3-Hexenoyl)-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly- Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu- Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2 |
| Molecular Formula | C221H366N72O67S |
| Appearance | Lyophilized White Powder |
| Source | Chemical Synthesis |
| Storage | Lyophilized Tesamorelin is stable at room temperature for 90 days; however, it is best stored in a freezer at -20°C for any extended period of time. |
| Terms | The products we offer are intended for laboratory research use only. Please familiarize yourself with our terms of service prior to ordering. |
| COA Verification | Verify this COA on MZ Biolabs → |
Tesamorelin 5mg
View Research Overview
Tesamorelin is a synthetic 44-amino-acid peptide based on the full-length sequence of growth hormone-releasing hormone (GHRH), with a trans-3-hexenoyl group attached to its N-terminus and an amidated C-terminus.
Laboratories use it in vitro as a modified ligand for the GHRH receptor and as a model for how N-terminal acylation alters peptide stability.
Peptide Structure and Chemistry
Unlike shorter GHRH fragments, tesamorelin carries the complete native sequence, including the C-terminal residues 30–44. This tail is rich in glutamine, glutamate, arginine and glycine, giving the full peptide a different charge distribution and solubility profile than the 1–29 segment alone.
Its two terminal modifications are:
- N-terminus: a trans-3-hexenoyl group, a six-carbon acyl chain with one double bond, attached to the α-amine of Tyr1
- C-terminus: an amide (Leu-NH2), matching the native peptide
At roughly 5.1 kDa, tesamorelin is considerably longer than most research peptides made by solid-phase synthesis, which makes purification and analytical verification more demanding than for short peptides.
The N-Terminal Hexenoyl Modification
The N-terminal Tyr-Ala sequence of native GHRH is a recognition site for dipeptidyl peptidase IV (DPP-IV), an enzyme that removes N-terminal dipeptides. DPP-IV generally requires a free N-terminal amine to act.
Acylating that amine with the hexenoyl group removes this requirement, and is understood to make the peptide a poor DPP-IV substrate. This is a common strategy in peptide design for protecting the N-terminus without changing the amino acid sequence itself.
The modification also adds a short hydrophobic tail at the N-terminus. Because the N-terminal region inserts deep into the receptor core during binding [1], this region is where the modification sits closest to the receptor.
The double bond in the hexenoyl group is in the trans (E) configuration. Its cis counterpart would have the same mass, so geometric configuration is one of the details analytical methods need to resolve.
Receptor Engagement
In cell-based systems, tesamorelin behaves as an agonist of the GHRH receptor, which belongs to the class B GPCR family and signals mainly through Gαs and cAMP.
Because tesamorelin shares the full native 1–44 sequence, structural data on the receptor bound to native GHRH apply closely. The cryo-EM structure of the receptor–Gs complex shows the ligand as an α-helix contacting the extracellular domain, all extracellular loops, and most transmembrane helices [1].
Receptor-mapping work in transfected cells has used radioiodinated GHRH(1–44)-amide as the binding probe, labeled at Tyr10 [2]. Those studies showed that both the receptor's N-terminal domain and its membrane-spanning region are needed for binding [2].
Chemical Stability in Solution
Acylation protects the N-terminus enzymatically, but it does not change the chemical liabilities shared by all GHRH-based sequences. Three positions account for most solution degradation:
- Asp3: cyclization to a succinimide, leading to β-aspartyl isomers [3]
- Asn8: deamidation through the same succinimide route [3]
- Met27: oxidation to methionine sulfoxide
These reactions depend on pH, temperature and time in solution. The full-length sequence also contains additional Gln and Asn residues in its C-terminal tail, which add further potential deamidation sites compared with the 1–29 segment.
Analytical Purity Verification
Identity and purity for a peptide of this length are usually established together: reversed-phase chromatography separates related impurities, while mass spectrometry confirms the intact molecule. At this size, electrospray mass spectra show a series of multiply charged ions rather than a single peak, and the intact mass is reconstructed from that series.
Analytical checks for this peptide commonly look for:
- Des-hexenoyl peptide, missing the N-terminal acyl group
- Met27 sulfoxide (+16 Da)
- Deamidated and β-aspartyl isomers
- The cis-hexenoyl isomer, which has the same mass
- Truncated and deletion sequences from synthesis
The average molecular weight is approximately 5135.9 g/mol, and the monoisotopic mass is approximately 5132.7 Da. Supplied acetate salt adds counterion mass on top of these peptide values, which matters when converting powder weight to molar concentration.
Storage and Handling in the Laboratory Setting
As a dry powder, tesamorelin is best held in a freezer in its sealed vial. Letting a cold vial warm fully before the cap comes off prevents condensation from forming on the powder.
In solution, the Asp, Asn and Met pathways described above begin to proceed. Laboratories usually reconstitute only what an experiment needs, hold working solutions cold and shielded from light, and split stock into single-use portions rather than refreezing it repeatedly.
Comparison With Shorter GHRH Fragments
Researchers often choose between full-length and truncated GHRH sequences depending on the question. The 44-residue form preserves the complete native C-terminal tail, while shorter fragments remove it.
Tesamorelin combines the full native sequence with N-terminal protection. That makes it useful in vitro for separating the effects of sequence length from the effects of N-terminal modification when comparing GHRH-based peptides side by side.
References
- Zhou F, Zhang H, Cong Z, et al. Structural basis for activation of the growth hormone-releasing hormone receptor. Nat Commun. 2020;11:5205. doi:10.1038/s41467-020-18945-0
- DeAlmeida VI, Mayo KE. Identification of binding domains of the growth hormone-releasing hormone receptor by analysis of mutant and chimeric receptor proteins. Mol Endocrinol. 1998;12(5):750–765.
- Bongers J, Heimer EP, Lambros T, Pan YCE, Campbell RM, Felix AM. Degradation of aspartic acid and asparagine residues in human growth hormone-releasing factor. Int J Pept Protein Res. 1992;39:364–374.
Important Notice
Tesamorelin is provided exclusively for laboratory research purposes (in vitro). This peptide is not intended for human consumption or use, and any application outside of controlled laboratory research is prohibited. These findings do not establish safety, efficacy, or suitability for any human application, and have not been evaluated by the FDA or any regulatory agency.
Product Information
Tesamorelin is supplied as a lyophilized powder for laboratory research use only.
CJC-1295 W-DAC 2mg$32.47
IPAMORELIN 2000mcg$27.27
Storage Case (10)$9.99





